19151 results
-
List item
Withdrawn application: Graspa
asparaginase, date of withdrawal: 22/06/2018, Initial authorisation, Last updated: 23/01/2019application for Graspa (L-asparaginase) On 22 June 2018, Erytech … contains the active substance L-asparaginase that has been enclosed in … enclosed in red blood cells. Asparaginase has been used to treat cancer … -
List item
Human medicine European public assessment report (EPAR): Ryzodeg
insulin aspart, insulin degludec, Diabetes Mellitus
Date of authorisation: 21/01/2013, Revision: 13, Authorised, Last updated: 23/09/2021Active substance insulin aspart insulin degludec International … insulin degludec insulin aspart Therapeutic area (MeSH) Diabetes … Marketing-authorisation holder Novo Nordisk A/S Revision 13 Date of issue … -
List item
Orphan designation: Recombinant human mesencephalic astrocyte-derived neurotrophic factor for: Treatment of retinitis pigmentosa
Date of designation: 24/04/2015, Positive, Last updated: 24/01/2023ombinant human mesencephalic astrocyte-derived neurotrophic factor … Recombinant human mesencephalic astrocyte-derived neurotrophic factor for the … recombinant human mesencephalic astrocyte-derived neurotrophic factor for … -
List item
Orphan designation: Asciminib for: Treatment of chronic myeloid leukaemia
Date of designation: 24/03/2020, Positive, Last updated: 07/09/2022Asciminib … Scemblix Scemblix asciminib Asciminib asciminib hydrochloride … application/pdf orphan medicine assessment report . … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sycrest, Asenapine maleate
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Psychiatry
PIP number: EMEA-000228-PIP01-08-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Sublingual tablet
Decision date: 24/11/2014, Last updated: 02/03/2018, Compliance check: V, 18/08/2017Sycrest Active substance Asenapine maleate Therapeutic area … paediatric investigation plan for asenapine (maleate) (Sycrest) (EMEA-000228-PIP01-08-M04 … paediatric investigation plan for asenapine (maleate) (Sycrest) (EMEA-000228-PIP01-08-M04 … -
List item
Orphan designation: Asp-Arg-Val-Tyr-Ile-His-Pro for: Treatment of acute lung Injury
Date of designation: 10/10/2012, Withdrawn, Last updated: 19/01/2016Asp-Arg-Val-Tyr-Ile-His-Pro … opinion on orphan designation Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of acute … opinion on orphan designation Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of acute … -
List item
Human medicine European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (updated)
ChAdOx1-SARS-COV-2, COVID-19 virus infection
Date of authorisation: 29/01/2021,
, Revision: 30, Authorised, Last updated: 21/09/2023
previously COVID-19 Vaccine AstraZeneca) Myelitis Respiratory Tract … used? Vaxzevria is given as two injections, usually into … medicine for end-users, such as patients and animal owners … -
List item
Human medicine European public assessment report (EPAR): Trizivir
abacavir (as sulfate), lamivudine, zidovudine, HIV Infections
Date of authorisation: 27/12/2000, Revision: 42, Authorised, Last updated: 27/09/2022abacavir (as sulfate) / lamivudine / zidov … contains 300 mg of abacavir (as sulfate), 150 mg lamivudine … section 4.4). Therefore, as dose adjustments of these … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ramipril, amlodipine (as besylate)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-003070-PIP01-21, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 03/12/2021, Last updated: 14/03/2023, Compliance check: Xfacts Ramipril amlodipine (as besylate) Cardiovascular … Regulation (EC) No 1901/2006 as amended, 1A Pharma GmbH submitted … Paediatric Committee, having assessed the waiver application in … -
List item
Human medicine European public assessment report (EPAR): Spherox
spheroids of human autologous matrix-associated chondrocytes, Cartilage Diseases
Date of authorisation: 10/07/2017, Revision: 8, Authorised, Last updated: 20/02/2023of human autologous matrix-associated chondrocytes … human autologous matrix- associated chondrocytes) An overview … experiencing symptoms (such as pain and problems moving … -
List item
Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding
Active substance: ChAdOx1-SARS-COV-2, DHPC type: Safety signal, Last updated: 13/10/2021previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia … thrombocytopenia) with or without associated bleeding COVID-19 virus … previously COVID-19 Vaccine AstraZeneca): risk of thrombocytopenia … -
List item
Direct healthcare professional communication (DHPC): Vaxzevria/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with thrombocytopenia - Updated information
Active substance: ChAdOx1-SARS-COV-2, DHPC type: Type II variation, Last updated: 02/06/2021Vaxzevria/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination … Vaxzevria/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination … VAXZEVRIA/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination … -
List item
Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): contraindication in individuals with previous capillary leak syndrome
Active substance: ChAdOx1-SARS-COV-2, DHPC type: Safety signal, Last updated: 23/06/2021previously COVID-19 Vaccine AstraZeneca): contraindication in individuals … previously COVID-19 Vaccine AstraZeneca): contraindication in individuals … VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals … -
List item
Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia
Active substance: ChAdOx1-SARS-COV-2, DHPC type: Safety signal, Last updated: 13/04/2021previously COVID-19 Vaccine AstraZeneca): link between the vaccine … previously COVID-19 Vaccine AstraZeneca): link between the vaccine … VAXZEVRIA/COVID-19 Vaccine AstraZeneca: link between the vaccine … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Strensiq, asfotase alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: EMEA-000987-PIP01-10-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 15/05/2019, Last updated: 21/09/2021, Compliance check: V, 18/10/2019Strensiq Active substance asfotase alfa Therapeutic area Endocrinology-Gynaecology-Fertility-Metabolism … Strensiq Strensiq asfotase alfa asfotase alfa asfotase alfa … -
List item
Human medicine European public assessment report (EPAR): Reyataz (updated)
atazanavir (as sulfate), HIV Infections
Date of authorisation: 01/03/2004, Revision: 54, Authorised, Last updated: 30/08/2023website. European public assessment reports include the product … information. Abbreviated as EPAR. More information … found under 'European public assessment reports - background and … -
List item
Herbal medicinal product: Centellae asiaticae herba
Centella asiatica (L.) Urb., Centella, F: Assessment finalised, Last updated: 02/09/2022Centellae asiaticae herba Skin disorders and … information. Key facts Centellae asiaticae herbaCentellaCentella asiatica (L.) Urb. Skin disorders … disorders and minor woundsF: Assessment finalised 31/10/2007 08/05/2008 … -
List item
Referral: Methylphenidate Sandoz
methylphenidate hydrochloride, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 25/07/2013, EC decision date: 09/10/2013, Last updated: 05/12/2013Methylphenidate Sandoz … by Pharmacovigilance Risk Assessment Committee Opinion provided … medicine Methylphenidate Sandoz. The Agency's Committee for … -
List item
Referral: Budesonide Sandoz
budesonide, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 20/02/2009, EC decision date: 07/05/2009, Last updated: 25/06/2009Budesonide Sandoz … by Pharmacovigilance Risk Assessment Committee Opinion provided … of the medicine Budesonide Sandoz. The Agency's Committee for … -
List item
Referral: Calcium Sandoz
Calcium lactate gluconate, Calcium carbonate, Article 30 referrals
Status: European Commission final decision, opinion/position date: 21/04/2005, EC decision date: 09/08/2005, Last updated: 09/08/2005Calcium Sandoz … by Pharmacovigilance Risk Assessment Committee Opinion provided … medicinal product Calcium Sandoz Effervescent tablets, 500/1000 … -
List item
Referral: Cefuroximaxetil
cefuroxime (as axetil), Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 26/04/2007, EC decision date: 22/08/2007, Last updated: 24/09/2007by Pharmacovigilance Risk Assessment Committee Opinion provided … Overview Cefuroximaxetil and associated names, 125 mg, 250 mg and … susceptible to cefuroxime, such as: upper respiratory tract infections … -
List item
Orphan designation: L-asparaginase encapsulated in erythrocytes for: Treatment of acute lymphoblastic leukaemia
Date of designation: 27/10/2006, Positive, Last updated: 29/07/2008L-asparaginase encapsulated in erythrocytes … ORPHAN DESIGNATION OF L-asparaginase encapsulated in erythrocytes … Pharma S.A., France, for L-asparaginase encapsulated in erythrocytes … -
List item
Summary of opinion: Frontpro (previously known as Afoxolaner Merial)
afoxolaner, opinion date: 09/09/2021, Positive, Last updated: 10/09/2021Frontpro (previously known as Afoxolaner Merial): Pending … Frontpro (previously known as Afoxolaner Merial … Frontpro is currently authorised as chewable tablets for use … -
List item
Referral: Mometasone Furoate Sandoz
mometasone furoate, associated names: Mometasone Sandoz, Mometasone Sandoz 50, Mometasone Furoato Sandoz 50, Mommox, Nasometi, Fumomo 50, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 19/07/2012, EC decision date: 08/10/2012, Last updated: 24/01/2013Mometasone Furoate Sandoz … by Pharmacovigilance Risk Assessment Committee Opinion provided … medicine Mometasone Furoate Sandoz. The Agency's Committee for … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-002862-PIP01-20-M02, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension for injection
Decision date: 27/12/2021, Last updated: 28/03/2023, Compliance check: Xpreviously COVID-19 Vaccine AstraZeneca) Active substance COVID-19 … Contact for public enquiries AstraZeneca AB Tel. +46 855324400 … application submitted by AstraZeneca AB on 13 September 2021 under …